Rheumatic Disease Unit, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.
J Diet Suppl. 2021;18(3):248-260. doi: 10.1080/19390211.2020.1757798. Epub 2020 May 18.
BACKGROUND/OBJECTIVE: Hyperuricemia leads to gout and renal complications and may increase cardiovascular risk. Curcumin inhibits xanthine oxidase and increases uricosuric activity and, as a result, decreases serum urate (SU). This randomized controlled trial aimed to determine the effects of curcumin versus placebo on SU in subjects with asymptomatic hyperuricemia (SU level ≥ 6 mg/dL in women or ≥ 7 mg/dL in men).
Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects). Primary outcome was the difference between SU before and 8 weeks after randomization. Secondary outcomes were differences between urine uric acid (UUA) clearance, fasting plasma glucose (FPG), and lipid profiles before and 8 weeks after randomization and adverse events.
Out of 39 subjects, there were no differences at baseline SU, UUA clearance, FPG, lipid profiles, and demographics between curcumin and placebo groups. After 8 weeks, SU was significantly decreased in both groups (6.9% in curcumin group, = 0.002, and 5.0% in placebo group, = 0.009). However, there was no difference in SU reduction between the two groups ( = 0.532). There were no differences in UUA, FPG, lipid profiles, or adverse events in either group at 8 weeks after randomization. The most common adverse event was diarrhea with no treatment required.
Curcumin was not superior to placebo in reducing serum urate and in increasing UUA clearance.
背景/目的：高尿酸血症可导致痛风和肾脏并发症，并可能增加心血管风险。姜黄素可抑制黄嘌呤氧化酶，增加尿酸排泄，从而降低血清尿酸（SU）。本随机对照试验旨在确定姜黄素与安慰剂对无症状高尿酸血症（女性 SU 水平≥6mg/dL 或男性 SU 水平≥7mg/dL）患者 SU 的影响。
39 例持续性高尿酸血症患者随机分为姜黄素组（500mg 胶囊，每日 2 次，20 例）或安慰剂组（19 例）。主要结局为随机分组前和 8 周后 SU 的差异。次要结局为随机分组前和 8 周后尿尿酸（UUA）清除率、空腹血糖（FPG）和血脂谱的差异以及不良事件。
39 例患者中，姜黄素组和安慰剂组在基线 SU、UUA 清除率、FPG、血脂谱和人口统计学方面无差异。8 周后，两组 SU 均显著降低（姜黄素组降低 6.9%， = 0.002，安慰剂组降低 5.0%， = 0.009）。但两组 SU 降低无差异（ = 0.532）。8 周后，两组 UUA、FPG、血脂谱或不良事件均无差异。最常见的不良事件是腹泻，无需治疗。
姜黄素在降低血清尿酸和增加 UUA 清除率方面并不优于安慰剂。
